Fortschritte der Neurologie · Psychiatrie
June 8, 2026
Udo Bonnet, Norbert Scherbaum, Georg Juckel et al.
Introduction: Esketamine nasal spray (EN) has been approved in Germany since 2021 for the treatment of treatment-resistant depression (TRD). Historically, the development of EN resulted from the positive results of randomized clinical trials on the off-label use of subnarcotic ketamine infusions (SKI) for TRD. How effective, tolerable, and safe is off-label SKI compared to EN? Methods: Narrativ...
Frontiers in Psychiatry
2022
Udo Bonnet, Michael Specka, Ann-Kristin Kanti et al.
4 citations
There is a lack of benefit/harm assessments of illicit and licit psychoactive substances performed by substance-dependent users in comparison to addiction medicine experts. We extended the analyses of substance harm/benefit assessments of German addiction medicine experts (N = 101), in parts reported recently in this journal [doi.org/10.3389/fpsyt.2020.59219], by the perspectives of...
Frontiers in Psychiatry
July 7, 2020
Michael Specka, Thomas Kuhlmann, Jürgen Sawazki et al.
42 citations
Background About 15 years ago, a diverse group of new recreational psychotropic substances began to emerge, which were marketed for example as “legal highs,” “research chemicals,” or “designer drugs.” These substances were later subsumed under the label “Novel Psychoactive Substances” (NPS). Important NPS classes are cathinones, synthetic cannabimimetics, phenethylamines, and herbal drugs. The...
Pharmacopsychiatry
April 25, 2017
Norbert Scherbaum, Fabrizio Schifano, Udo Bonnet
46 citations
Over the last few years, hundreds of new psychoactive substances (NPS) have been identified in Europe. Apart from some herbal compounds, NPS mainly include synthetic cannabinoids and a range of new synthetic stimulants (e. g., cathinones). Synthetic NPS are often developed whilst modifying the basic chemical (e. g., phenethylamine or tryptamine) structure. Although the pharmacology and...
Life Sciences
January 1, 2017
Udo Bonnet
Ketamine is approved to start and maintain anaesthesia or analgesia. Ketamine is also known to be neurotoxic and an old drug of abuse. Numerous studies have proven a rapid and strong antidepressant response (AR) following parenteral sub-anaesthetic ketamine doses when applied the first time to patients with treatment resistant unipolar or bipolar major depression. This rapid and robust AR is...
The British Journal of Psychiatry
November 1, 2016
Udo Bonnet
hospitalisation and recovery.Somewhere in the journey, I realised that I am a person with mental illness -that it is as much a part of my identity as fatherhood or professionalism.I am proud of all of these identities.I do not want to have to keep any of them a secret by passing as normal.Instead, I expect others to join me where I stand.1 Corrigan PW.Resolving mental illness stigma: should we...